Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Georges Gebrael(University of Utah), Toni K. Choueiri(Harvard University), Anil Kapoor(People’s University), Audreylie Lemelin(University of Calgary), Naveen S. Basappa, J. Connor Wells(Queen's University), Renée Maria Saliby(Yale University), Karl Semaan(Broad Institute), Matthew Scott Ernst(University of Calgary), Kosuke Takemura(Japanese Foundation For Cancer Research), Wanling Xie(Dana-Farber Cancer Institute), Nicolas Sayegh(Huntsman Cancer Institute), D. Scott Ernst, Lori Wood(Dalhousie University), Marc Eid(Harvard University), Thomas Powles(National Health Service), Neeraj Agarwal(University of Utah), Chris Labaki(Beth Israel Deaconess Medical Center), Daniel Yick Chin Heng(University of Calgary), Eddy Saad(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k